| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TCEAL1 |
| Uniprot No | Q15170-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-159aa |
| 氨基酸序列 | MDKPRKENEEEPQSAPKTDEERPPVEHSPEKQSPEEQSSEEQSSEEEFFP EELLPELLPEMLLSEERPPQEGLSRKDLFEGRPPMEQPPCGVGKHKLEEG SFKERLARSRPQFRGDIHGRNLSNEEMIQAADELEEMKRVRNKLMIMHWK AKRSRPYPILEHHHHHH |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TCEAL1重组蛋白的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**: *TCEAL1 modulates the transcriptional activity of E2F1 by physically interacting with the E2F1 promoter*
**作者**: Li Y, et al.
**摘要**: 该研究通过重组TCEAL1蛋白的体外实验，发现其能够直接结合E2F1启动子区域，并通过调控组蛋白修饰抑制E2F1的转录活性，从而影响细胞周期进程，可能在卵巢癌中发挥肿瘤抑制作用。
---
2. **文献名称**: *Functional characterization of TCEAL1 as a tumor suppressor in breast cancer via recombinant protein-mediated pathway analysis*
**作者**: Smith J, et al.
**摘要**: 作者利用重组TCEAL1蛋白进行功能研究，证明其通过抑制Wnt/β-catenin信号通路抑制乳腺癌细胞增殖和迁移，并发现TCEAL1的N端结构域对结合β-catenin至关重要。
---
3. **文献名称**: *Structural insights into the TCEAL1-Cullin 3 interaction by recombinant protein co-purification assays*
**作者**: Kumar R, et al.
**摘要**: 通过重组表达TCEAL1与Cullin 3蛋白的复合物，研究揭示了TCEAL1通过特定的Kelch结构域与Cullin 3相互作用，可能参与泛素化调控通路，为理解其在癌症中的异常表达提供结构基础。
---
**备注**：以上文献信息为示例性内容，实际研究中建议通过PubMed或Web of Science检索最新发表的论文以获取准确数据。
**Background of TCEAL1 Recombinant Protein**
TCEAL1 (Transcription Elongation Factor A Like 1) is a member of the transcription elongation factor family, which plays a role in regulating gene expression by modulating RNA polymerase II activity. It is encoded by the *TCEAL1* gene located on the X chromosome and contains a conserved TCEAL domain, suggesting its involvement in protein-protein or protein-DNA interactions. TCEAL1 is implicated in diverse cellular processes, including cell proliferation, differentiation, and apoptosis, and has been linked to cancer pathogenesis, particularly in ovarian and breast cancers, where it may act as a tumor suppressor or oncogene depending on cellular context.
Recombinant TCEAL1 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional protein for research applications. Its recombinant form enables detailed studies of TCEAL1's molecular mechanisms, such as its interaction with transcriptional regulators (e.g., c-Myc, p53) or its role in signaling pathways like Wnt/β-catenin. Researchers utilize this protein to investigate its regulatory effects on cancer-related genes and to explore its potential as a therapeutic target or biomarker.
Studies suggest TCEAL1 may influence chromatin remodeling and epigenetic modifications, further linking it to transcriptional dysregulation in diseases. However, its exact biological functions remain partially unresolved, necessitating further structural and functional analyses. The availability of recombinant TCEAL1 accelerates experimental workflows, including antibody development, protein interaction assays, and in vitro functional studies, ultimately contributing to a deeper understanding of its role in health and disease.
×
